The hard-endpoint trial the tricuspid field lacked: 360 patients (mean 80 years, 56 percent women) with heart failure and severe tricuspid regurgitation in 29 German centres, randomised 2:1 to transcatheter edge-to-edge repair (98 percent) plus medical therapy or medical therapy alone. One-year hierarchical endpoint win ratio 2.42 (95% CI 1.76 to 3.33, p under 0.001); freedom from death or HF hospitalisation at three years 52.4 versus 21.0 percent (HR 0.40, 0.29 to 0.55). Hot Line 7, NEJM.
